Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiCombination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumoniaNatural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiOptimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Biofilms and host response - helpful or harmful.Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Optimization and evaluation of piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling.
P2860
Q26771850-6E35F928-6D67-406B-BD83-252F5739A085Q30837114-A6CC4551-7598-4493-BD9B-52E04D8F6B90Q35168931-DAA9B9BA-FF70-4D5C-A1E2-1EC8CA7916F6Q35661926-88045D3C-A796-4BA9-80DD-7274AF6CE9E9Q36644836-11BD53E9-0E3B-4DD4-9B20-7916E852663FQ36915742-F07DD6EA-8B82-4CC1-8A7B-3EC7AB2B91A3Q37023206-6A3DB071-9A4C-4A94-9F81-5A2C4B03A8BEQ37538623-FEA9B08F-86D3-4F15-B9A0-0EE62083368FQ39240791-C73DF6AB-248E-44E8-8D42-2E49C50DBDD6Q40657200-50DDF9A2-0F49-428F-A77C-DE07FED4A5FAQ40719307-68B95357-38D0-4FBC-873F-DFD7064F8793Q47567107-A1CD38F9-36F7-49E6-B1D7-D8F2D0359587Q47656109-3C714537-81E5-4433-A5C2-FAFC2C932069Q49792113-A72916E9-9D1B-48A0-9979-347EC7F4E01D
P2860
Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Interaction of drug- and granu ...... a in a murine pneumonia model.
@ast
Interaction of drug- and granu ...... a in a murine pneumonia model.
@en
Interaction of drug- and granu ...... a in a murine pneumonia model.
@nl
type
label
Interaction of drug- and granu ...... a in a murine pneumonia model.
@ast
Interaction of drug- and granu ...... a in a murine pneumonia model.
@en
Interaction of drug- and granu ...... a in a murine pneumonia model.
@nl
prefLabel
Interaction of drug- and granu ...... a in a murine pneumonia model.
@ast
Interaction of drug- and granu ...... a in a murine pneumonia model.
@en
Interaction of drug- and granu ...... a in a murine pneumonia model.
@nl
P2093
P2860
P356
P1476
Interaction of drug- and granu ...... a in a murine pneumonia model.
@en
P2093
Arnold Louie
David Brown
Dodge Baluya
George Louis Drusano
Jaime Rodriquez
Nichole Robbins
Stephanie Kurhanewicz
Steven Fikes
Weiguo Liu
P2860
P304
P356
10.1093/INFDIS/JIU237
P407
P577
2014-04-22T00:00:00Z